Fuji Pharma Raises ¥3.3 Billion as 2nd Series Stock Acquisition Rights Fully Exercised

The latest update is out from Fuji Pharma Co., Ltd. ( (JP:4554) ).

Fuji Pharma Co., Ltd. announced that the entire 2nd Series of Stock Acquisition Rights, issued via third-party allotment to Nomura Securities Co., Ltd. in August 2024, has been fully exercised as of March 11, 2026. The exercise of all 16,500 units raised 3.3 billion yen in funds, leaving no remaining rights outstanding.

Following the completion of this exercise, Fuji Pharma reported a total of 26,541,100 issued shares and capital of 5,555,919,505 yen as of March 11, 2026. The full exercise strengthens the company’s equity base and provides additional capital that can support its ongoing operations and strategic initiatives in the pharmaceutical market.

The most recent analyst rating on (JP:4554) stock is a Buy with a Yen2651.00 price target. To see the full list of analyst forecasts on Fuji Pharma Co., Ltd. stock, see the JP:4554 Stock Forecast page.

More about Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of prescription drugs and related medical products. The company serves healthcare providers and patients primarily in Japan, positioning itself as a specialized player in the domestic drug market.

Average Trading Volume: 163,989

Technical Sentiment Signal: Buy

Current Market Cap: Yen55.81B

See more data about 4554 stock on TipRanks’ Stock Analysis page.